Literature DB >> 6847012

Human essential hypertension: implications of animal studies.

L Tobian.   

Abstract

Hypertension has been linked to dietary sodium intake in humans. It is possible that 9% to 20% of the population may be genetically susceptible to developing essential hypertension by middle life. The remainder of the population may be genetically resistant to developing essential hypertension. A person genetically resistant to hypertension can ingest as much as 200 meq/d of salt without developing elevated blood pressure. However, in persons genetically susceptible to hypertension, a lifelong restriction of salt intake of less than 60 meq/d in adults may prevent hypertension indefinitely, and subsequent hypertensive complications. The same restriction of salt enhances the effect of most antihypertensive drugs and is the only treatment necessary in some persons with mild or moderate hypertension, especially the elderly.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847012     DOI: 10.7326/0003-4819-98-5-729

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

1.  Wild garlic has a greater effect than regular garlic on blood pressure and blood chemistries of rats.

Authors:  H G Preuss; D Clouatre; A Mohamadi; S T Jarrell
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Blood pressure development of the spontaneously hypertensive rat after concurrent manipulations of dietary Ca2+ and Na+. Relation to intestinal Ca2+ fluxes.

Authors:  D A McCarron; P A Lucas; R J Shneidman; B LaCour; T Drüeke
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

3.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance.

Authors:  M Modan; H Halkin; S Almog; A Lusky; A Eshkol; M Shefi; A Shitrit; Z Fuchs
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

4.  Sodium and hypertension. Still a controversy in 1986.

Authors:  E A Francischetti; V G de Abreu Fagundes; W Oigman
Journal:  Drugs       Date:  1986       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.